Program Topics

How effective is HPV genotyping in screening?
- J. Bonde (Denmark)
- J. Dillner (Sweden)
Cervical cancer screening: Harms and benefit ratio in the changing world of cervical cancer screening
- M. Rebolj (UK)
- S. Van Dijk (Netherlands)
Screening for HPV-vaccinated cohorts: Country-specific experience
- J. Lei (Sweden)
- P. Sasieni (UK)
The utility of urine for improved cervical cancer prevention
- A. Vorsters (Belgium)
Risk stratification in cervical cancer screening
- H. Berkhof (Netherlands)
- F. Inturrisi (Netherlands)
Self-sampling
- G. Ogilvie (Canada)
- M. Saville (Australia)
Self-sampling implementation
- J. Bonde (Denmark)
- M. Poljak (Slovenia)
What role of cytology in HPV screening: Are we really ready to abandon morphological data completely and use only virological data?
- F. Carozzi (Italy)

Gender-neutral vaccination: Impact on speed of elimination and subsequent need for screening
- E. Franco (Canada)
- M. Lehtinen (Finland)
One-dose vaccination: What do we know, what will we know and what are the remaining evidence gaps?
- M. Brisson (Canada)
- M. Jit (UK)
Vaccination hesitancy, recovery and public advocacy
- S. Hanley (UK)
- I. Olkov (France)
PERCH(PartnERship to Contrast HPV): an EU Joint Action aiming for improved HPV vaccination coverage and data collection
- M. Arbyn (Belgium)
- R. Bucciardini (Italy)
Scientific approaches to definition of HPV vaccine-induced protective immunity
- S. Beddows (UK)
- J. Dillner (Sweden)
- M. Lehtinen (Finland)
Multi-sector partnerships to accelerate HPV vaccination: Real world evidence
- M. Fisher-Borne (USA)

Use of genotyping for management
- F. Carozzi (Italy)
- F. Inturrisi (Netherlands)
How to deal with persistent HPV without HSIL lesions in colposcopy
- K. Louvanto (Finland)
Vaccination in women with CIN treatment
- P. Nieminen (Finland)
- B. Strander (Sweden)
Colposcopy
- G. Donders (Belgium)
HPV genital diseases during pregnancy
- K. Louvanto (Finland)
- E. Siegler (Israel)

Putting anal cancer screening into practice: Implementation science, biomarker development, and self-sampling
- A. Burchell (Canada)
- A. Nyitray (USA)
Implementation of anal cancer screening: Challenges and solutions
- J. Palefsky (USA)

Research to advance prevention of cervical and HPV-related cancers among women living with HIV
- A. Giuliano (USA)
- V. Sahasrabuddhe (USA)
Sexual abuse and HPV
- A. B. Moscicki (USA)
HPV driven cancer among people living with HIV
- A. B. Moscicki (USA)
- M. Muchengeti (South Africa)
Cervical cancer screening in LMICs
- J. Smith (USA)
Screening for HPV-related cancer in sexual and gender minority adults
- S. Jackson (USA)
- A. Kreimer (USA)
HPV vaccination in vulnerable populations
- M. Bardou (France)
- I. Baussano (France)

Validation of HPV assays
- M. Arbyn (Belgium)
- K. Cuschieri (UK)
Global overview of commercial HPV tests: 2024 status
- K. Cuschieri (UK)
- M. Poljak (Slovenia)
Methylation markers as management tool in anal, vulvar and cervical intraepithelial neoplasms
- M. Bleeker (Netherlands)
- M. Clarke (USA)
Indications for methylation testing in cervical screening and in the diagnosis of cervical and non-cervical HPV-associated lesions
- D. Heideman (Netherlands)
- R. Steenbergen (Netherlands)
Newest insights into oncogenesis
- R. Steenbergen (Netherlands)
Present status of genome-wide association studies
- P. Hillemanns (Germany)
Microbiome
- C. Bouchard (Canada)
- G. Ogilvie (Canada)
Newest insights into HPV epidemiology
- S. Franceschi (Italy)
- A. Kreimer (USA)
Challenges and implications of viral load and cellularity measurements
- M. Arbyn (Belgium)
- C. Cocuzza (Italy)
Global HPV laboratory network
- S. Arroyo Mühr (Sweden)
- K. Cuschieri (UK)

Coordinators: C. Brenner (USA) - J. P. Klussmann (Germany) - K. Lang Kuhs (USA) - S. Virani (France)